US 2026/0258124 A1 · ANTIBODIES TARGETING CD117

Antibodies targeting cd117

AssigneesCimeio Therapeutics AG, UniversitäT Basel

InventorsStefanie URLINGER, Anna CAMUS, Rosalba LEPORE, Alessandro SINOPOLI, Amélie WIEDERKEHR, Lukas JEKER, Frank LEHMANN, Anna HAYDN, Mathilde TESTUT, Lisa WELLINGER, Laura GARCIA PRAT, Emiel TEN BUREN, Melanie HUG

Life of this patent

Estimating the term…

Abstract

The present disclosure relates to antibodies and antibody fragments that are specific for CD117. The antibodies are improved versions of state-of-the art antibodies. In addition to a sophisticated humanization campaign, the antibodies were also engineered to remove several detrimental motifs within the CDR region without losing any beneficial properties. The antibodies are useful for the treatment of diseases associated with CD117.

Claims16

Dependent claims

-15. (canceled)

A humanized antibody or antibody fragment specific for human CD117, wherein said antibody or antibody fragment comprises a variable heavy chain comprising a HCDR1 region of SEQ ID NO:

4, a HCDR2 region of SEQ ID NO:
5, a HCDR3 region of SEQ ID NO:
6 and a variable light chain comprising, the LCDR1 region of SEQ ID NO:
7, the LCDR2 region of SEQ ID NO:
8 and the LCDR3 region of SEQ ID NO:
9, wherein said humanized antibody or antibody fragment has at least a mutation in which the asparagine in the LCDR1 region (SEQ ID NO:
7) is replaced by glutamic acid or tyrosine.

4 more elements

Dependencies are inferred from the claim text.